Loading…
EIKN
Eikon Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$10.98-4.69%
Key metrics
- Market cap
- $594.73M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.3x
- Dividend yield
- —
- EPS
- -$5.65
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $17.40
- 52-week low
- $7.90
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
- 384
- Millbrae, United States
Company description provided by Yahoo Finance.